Serum is not required for ex vivo IFN-gamma ELISPOT: a collaborative study of different protocols from the European CIMT Immunoguiding Program
- PMID: 20052465
- PMCID: PMC2813523
- DOI: 10.1007/s00262-009-0814-4
Serum is not required for ex vivo IFN-gamma ELISPOT: a collaborative study of different protocols from the European CIMT Immunoguiding Program
Abstract
The Cancer Immunotherapy Immunoguiding Program has conducted an IFN-gamma ELISPOT proficiency panel to examine the influence of serum supplementation of test media on assay performance. Sixteen European laboratories analyzed the same PBMC samples using different locally established protocols. Participants generated two simultaneous data sets-one using medium supplemented with serum and one without serum. Performances of the two test conditions were compared by quantifying: (1) the number of viable cells, (2) background spot formation induced in the medium only control and (3) the ability to detect antigen-specific T cell responses. The study demonstrated that the number of viable cells recovered and the overall background spot production were not significantly different between the two conditions. Furthermore, overall laboratory performance was equivalent for the two test conditions; 11 out of 16 laboratories reported equal or greater detection rates using serum-free medium, while 5 laboratories reported decreased detections rates under serum-free conditions. These results show that good performance of the IFN-gamma ELISPOT assay can be achieved under serum-free conditions. Optimization of the protocol for serum-free conditions should result in excellent detection rates and eliminate the requirement of serum batch and stability testing, allowing further harmonization of the assay.
Figures


Similar articles
-
Performance of serum-supplemented and serum-free media in IFNgamma Elispot Assays for human T cells.Cancer Immunol Immunother. 2010 Apr;59(4):609-18. doi: 10.1007/s00262-009-0788-2. Epub 2009 Nov 6. Cancer Immunol Immunother. 2010. PMID: 19894047 Free PMC article.
-
Serum-free freezing media support high cell quality and excellent ELISPOT assay performance across a wide variety of different assay protocols.Cancer Immunol Immunother. 2013 Apr;62(4):615-27. doi: 10.1007/s00262-012-1359-5. Epub 2012 Nov 9. Cancer Immunol Immunother. 2013. PMID: 23138872 Free PMC article.
-
Concordant proficiency in measurement of T-cell immunity in human immunodeficiency virus vaccine clinical trials by peripheral blood mononuclear cell and enzyme-linked immunospot assays in laboratories from three continents.Clin Vaccine Immunol. 2009 Feb;16(2):147-55. doi: 10.1128/CVI.00326-08. Epub 2008 Dec 17. Clin Vaccine Immunol. 2009. PMID: 19091991 Free PMC article.
-
[Evolution of IGRA researches].Kekkaku. 2008 Sep;83(9):641-52. Kekkaku. 2008. PMID: 18979999 Review. Japanese.
-
Validation of the performance and suitability of a new class of FBS optimized for use in single-cell functional assays.J Immunol Methods. 2023 Apr;515:113452. doi: 10.1016/j.jim.2023.113452. Epub 2023 Feb 28. J Immunol Methods. 2023. PMID: 36858170 Free PMC article. Review.
Cited by
-
Harmonization of the intracellular cytokine staining assay.Cancer Immunol Immunother. 2012 Jul;61(7):967-78. doi: 10.1007/s00262-012-1282-9. Epub 2012 May 22. Cancer Immunol Immunother. 2012. PMID: 22714399 Free PMC article.
-
Determination of CAR T cell metabolism in an optimized protocol.Front Bioeng Biotechnol. 2023 Jun 20;11:1207576. doi: 10.3389/fbioe.2023.1207576. eCollection 2023. Front Bioeng Biotechnol. 2023. PMID: 37409169 Free PMC article.
-
A phase I/IIa study of the mRNA-based cancer immunotherapy CV9201 in patients with stage IIIB/IV non-small cell lung cancer.Cancer Immunol Immunother. 2019 May;68(5):799-812. doi: 10.1007/s00262-019-02315-x. Epub 2019 Feb 15. Cancer Immunol Immunother. 2019. PMID: 30770959 Free PMC article. Clinical Trial.
-
Performance of serum-supplemented and serum-free media in IFNgamma Elispot Assays for human T cells.Cancer Immunol Immunother. 2010 Apr;59(4):609-18. doi: 10.1007/s00262-009-0788-2. Epub 2009 Nov 6. Cancer Immunol Immunother. 2010. PMID: 19894047 Free PMC article.
-
ELISpot for measuring human immune responses to vaccines.Expert Rev Vaccines. 2011 Mar;10(3):299-306. doi: 10.1586/erv.10.169. Expert Rev Vaccines. 2011. PMID: 21434798 Free PMC article. Review.
References
-
- Hoos A, Parmiani G, Hege K, Sznol M, Loibner H, Eggermont A, Urba W, Blumenstein B, Sacks N, Keilholz U, Nichol G. A clinical development paradigm for cancer vaccines and related biologics. J Immunother. 1997;30:1–15. doi: 10.1097/01.cji.0000211341.88835.ae. - DOI - PubMed
-
- Cox JH, Ferrari G, Kalams SA, Lopaczynski W, Oden N, D’souza MP. Results of an ELISPOT proficiency panel conducted in 11 laboratories participating in international human immunodeficiency virus type 1 vaccine trials. AIDS Res Hum Retroviruses. 2005;21:68–81. doi: 10.1089/aid.2005.21.68. - DOI - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical